DOI: http://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20211630

Osteonecrosis of bilateral femoral head in a post COVID-19 patient: case report

Ankith Chacko, Murukan Babu, Dibin K. Thomas

Abstract


Osteonecrosis of the femoral head, can be secondary to various causes, which can be traumatic or atraumatic. The corticosteroid used is a common cause of non-traumatic osteonecrosis. Various viral infections have been documented to cause osteonecrosis, none of the studies report COVID-19. 23-year-old gentleman diagnosed with COVID-19. He received steroid injections as a part of treatment. Nearly after two months, he was diagnosed to have stage II osteonecrosis of both femoral heads. The cumulative dose of steroid given to the patient was not enough to consider diagnosis of steroid associated osteonecrosis of femoral heads. The combination hypercoagulability, inflammation of blood vessels, and leukocyte/platelet aggregation associated with COVID-19 might have contributed to the development of osteonecrosis in this case. So, it is also important to consider osteonecrosis as an important differential if a patient with past history of COVID-19 come with hip pain.


Keywords


Osteonecrosis of the femoral head, COVID-19, Steroid associated osteonecrosis

Full Text:

PDF

References


Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev. 2010;9(11):721-43.

Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019;4(3):85-97.

Seamon J, Keller T, Saleh J, Cui Q. The Pathogenesis of Nontraumatic Osteonecrosis. Arthritis. 2012:1-11.

Koo KH, Kim R, Kim YS, Ahn IO, Cho SH, Song HR, et al. Risk Period for Developing Osteonecrosis of the Femoral Head in Patients on Steroid Treatment. Clin Rheumatol. 2002;21(4):299–303.

Chan MHM, Chan PKS, Griffith JF, Chan IHS, Lit LCW, Wong CK, et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology. 2006;38(3):229-35.

Yoon BH, Jones LC, Chen CH, Cheng EY, Cui Q, Drescher W, et al. Etiologic Classification Criteria of ARCO on Femoral Head Osteonecrosis Part 1: Glucocorticoid-Associated Osteonecrosis. J Arthroplasty. 2019;34(1):163-168.

Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal Consequences of COVID-19. J Bone Jt Surg. 2020 Jul 15;102(14):1197-204.

Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol. 2004;59(7):602-8.

Griffith J. Musculoskeletal Complications of Severe Acute Respiratory Syndrome. Semin Musculoskelet Radiol. 2011;15(5):554-60.

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101-15.

Maier CL, Truong AD, Auld SC, Polly DM, Tanksley C-L, Duncan A. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? The Lancet. 2020;395(10239):1758-9.

Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. Panthier J-J, editor. PLOS Genet. 2015;11(10):1005504.

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):438-40.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7.

Lykissas MG, Kostas-Agnantis IP, Gelalis ID, Vozonelos G, Korompilias AV. The role of hypercoagulability in the development of osteonecrosis of the femoral head. Orthop Rev. 2012;4(2):17.

Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020;324(8):799.

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.Sci China Life Sci. 2020;63(3):364-74.

Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. Subbarao K, editor. mBio. 2018;9(5):01753-18.

Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol. 1995;25(2S):13-9.

Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020;38(7):1488-93.

Zhang B, Zhang S. Corticosteroid‐Induced Osteonecrosis in COVID‐19: A Call For Caution. J Bone Miner Res. 2020;35(9):1828-9.